Aruna Bio

Executive Summary

Aruna Bio is a private biotechnology company pioneering a proprietary neural exosome platform to address the challenge of delivering therapeutics across the blood-brain barrier for neurological diseases. Its lead candidate, AB126, is a naturally derived neural exosome that leverages multiple mechanisms including neuroprotection and regeneration. By harnessing the innate ability of neural exosomes to cross the blood-brain barrier, Aruna Bio aims to develop disease-modifying treatments for conditions such as stroke, traumatic brain injury, and neurodegenerative disorders. The platform's versatility also enables the loading of siRNA, antisense oligonucleotides, or small molecules for targeted delivery. Aruna Bio is advancing AB126 through preclinical and early clinical development. The company has reported positive preclinical results demonstrating efficacy in models of acute neurological injury and is preparing for first-in-human studies. As a privately held entity, Aruna Bio's progress relies on securing funding through grants, partnerships, or venture capital. Key upcoming milestones include the filing of an Investigational New Drug (IND) application with the FDA, initiation of Phase 1 clinical trials, and potential strategic collaborations to expand its pipeline. The company's innovative approach and early data position it as a compelling player in the CNS drug delivery space.

Upcoming Catalysts (preview)

• Q3 2026IND filing for AB12680% success
• Q4 2026Initiation of Phase 1 clinical trial for AB12670% success
• TBDStrategic partnership or collaboration deal60% success